vs
Side-by-side financial comparison of Vericel Corp (VCEL) and VICOR CORP (VICR). Click either name above to swap in a different company.
VICOR CORP is the larger business by last-quarter revenue ($113.0M vs $92.9M, roughly 1.2× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 18.3%, a 6.7% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 20.2%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 14.7%).
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
VCEL vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $92.9M | $113.0M |
| Net Profit | $23.2M | $20.7M |
| Gross Margin | 78.7% | — |
| Operating Margin | 24.1% | 59.7% |
| Net Margin | 25.0% | 18.3% |
| Revenue YoY | 23.3% | 20.2% |
| Net Profit YoY | 17.3% | 713.9% |
| EPS (diluted) | $0.46 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $92.9M | $107.3M | ||
| Q3 25 | $67.5M | $110.4M | ||
| Q2 25 | $63.2M | $96.0M | ||
| Q1 25 | $52.6M | $94.0M | ||
| Q4 24 | $75.4M | $96.2M | ||
| Q3 24 | $57.9M | $93.2M | ||
| Q2 24 | $52.7M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $23.2M | $46.5M | ||
| Q3 25 | $5.1M | $28.3M | ||
| Q2 25 | $-553.0K | $41.2M | ||
| Q1 25 | $-11.2M | $2.5M | ||
| Q4 24 | $19.8M | $10.2M | ||
| Q3 24 | $-901.0K | $11.6M | ||
| Q2 24 | $-4.7M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 78.7% | 55.4% | ||
| Q3 25 | 73.5% | 57.5% | ||
| Q2 25 | 73.7% | 95.9% | ||
| Q1 25 | 69.0% | 47.2% | ||
| Q4 24 | 77.6% | 52.4% | ||
| Q3 24 | 71.9% | 49.1% | ||
| Q2 24 | 69.5% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 24.1% | 14.6% | ||
| Q3 25 | 5.1% | 18.9% | ||
| Q2 25 | -3.2% | 47.3% | ||
| Q1 25 | -24.3% | -0.2% | ||
| Q4 24 | 24.5% | 9.6% | ||
| Q3 24 | -4.3% | 5.8% | ||
| Q2 24 | -11.5% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | 25.0% | 43.4% | ||
| Q3 25 | 7.5% | 25.6% | ||
| Q2 25 | -0.9% | 42.9% | ||
| Q1 25 | -21.4% | 2.7% | ||
| Q4 24 | 26.3% | 10.7% | ||
| Q3 24 | -1.6% | 12.4% | ||
| Q2 24 | -8.9% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.46 | $1.01 | ||
| Q3 25 | $0.10 | $0.63 | ||
| Q2 25 | $-0.01 | $0.91 | ||
| Q1 25 | $-0.23 | $0.06 | ||
| Q4 24 | $0.40 | $0.24 | ||
| Q3 24 | $-0.02 | $0.26 | ||
| Q2 24 | $-0.10 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $137.5M | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $354.6M | $754.1M |
| Total Assets | $488.0M | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $137.5M | $402.8M | ||
| Q3 25 | $135.4M | $362.4M | ||
| Q2 25 | $116.9M | $338.5M | ||
| Q1 25 | $112.9M | $296.1M | ||
| Q4 24 | $116.2M | $277.3M | ||
| Q3 24 | $101.7M | $267.6M | ||
| Q2 24 | $102.5M | $251.9M |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $354.6M | $711.6M | ||
| Q3 25 | $321.9M | $630.1M | ||
| Q2 25 | $306.8M | $608.6M | ||
| Q1 25 | $295.5M | $580.3M | ||
| Q4 24 | $292.0M | $570.1M | ||
| Q3 24 | $257.5M | $554.6M | ||
| Q2 24 | $243.0M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $488.0M | $785.8M | ||
| Q3 25 | $453.3M | $710.2M | ||
| Q2 25 | $435.6M | $693.5M | ||
| Q1 25 | $424.6M | $665.0M | ||
| Q4 24 | $432.7M | $641.1M | ||
| Q3 24 | $390.4M | $632.8M | ||
| Q2 24 | $376.8M | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.0M | — |
| Free Cash FlowOCF − Capex | $12.8M | — |
| FCF MarginFCF / Revenue | 13.8% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | 0.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | $24.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $15.0M | $15.7M | ||
| Q3 25 | $22.1M | $38.5M | ||
| Q2 25 | $8.2M | $65.2M | ||
| Q1 25 | $6.6M | $20.1M | ||
| Q4 24 | $22.2M | $10.1M | ||
| Q3 24 | $10.2M | $22.6M | ||
| Q2 24 | $18.5M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $12.8M | $10.2M | ||
| Q3 25 | $19.5M | $34.5M | ||
| Q2 25 | $81.0K | $59.0M | ||
| Q1 25 | $-7.6M | $15.6M | ||
| Q4 24 | $8.5M | $8.4M | ||
| Q3 24 | $-9.2M | $14.1M | ||
| Q2 24 | $1.8M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 9.5% | ||
| Q3 25 | 28.8% | 31.2% | ||
| Q2 25 | 0.1% | 61.5% | ||
| Q1 25 | -14.5% | 16.6% | ||
| Q4 24 | 11.2% | 8.7% | ||
| Q3 24 | -15.9% | 15.2% | ||
| Q2 24 | 3.4% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 5.2% | ||
| Q3 25 | 3.9% | 3.6% | ||
| Q2 25 | 12.9% | 6.5% | ||
| Q1 25 | 27.0% | 4.8% | ||
| Q4 24 | 18.3% | 1.8% | ||
| Q3 24 | 33.5% | 9.1% | ||
| Q2 24 | 31.8% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.65× | 0.34× | ||
| Q3 25 | 4.35× | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | 1.12× | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
